<DOC>
	<DOCNO>NCT02933281</DOCNO>
	<brief_summary>MTBVAC four dose level : 5 x 10^3 CFU , 5 x 10^4 CFU , 5 x 10^5 CFU , 5 x 10^6 CFU . The active control BCG ( 5 x 10^5 CFU ) . Participants receive single dose MTBVAC BCG revaccination administer intradermally Study Day 0 .</brief_summary>
	<brief_title>MTBVAC Study Adults With Without Latent Tuberculosis Infection South Africa</brief_title>
	<detailed_description>This Phase 1b/2a , double-blind , randomize , BCG-controlled , dose-escalation safety immunogenicity study 120 healthy adult without LTBI . All participant receive previous BCG vaccination infancy . The investigational product MTBVAC four dose level : 5 x 10^3 CFU , 5 x 10^4 CFU , 5 x 10^5 CFU , 5 x 10^6 CFU . The active control BCG ( 5 x 10^5 CFU ) . Participants meet inclusion/exclusion criterion randomize within study cohort receive single dose MTBVAC BCG revaccination administer intradermally Study Day 0 . The study conduct one site South Africa . Participants enrol one eight cohort follow safety immunogenicity endpoint Study Day 182 . The estimated time complete enrolment approximately 9 month . Cohorts 1-8 include 60 QFT-negative ( Cohorts 1-4 ) 60 QFT-positive ( Cohorts 5-8 ) participant . Participants randomize within cohort , receive either MTBVAC ( N=96 ) BCG ( N=24 ) . The cohort enrol describe protocol , long pausing/stopping rule trigger</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Latent Tuberculosis</mesh_term>
	<criteria>1 . Has complete write informed consent process . 2 . Is male female age 18 50 year Study Day 0 . 3 . Agrees stay contact clinical trial site duration study , provide update contact information necessary , current plan move study area duration study . 4 . For female participant : agree avoid pregnancy 21 day prior Study Day 0 full duration study . Women physically capable pregnancy ( sterilize still menstruate within 1 year last menses menopausal ) sexual relationship men must use acceptable method avoid pregnancy period . Acceptable method avoid pregnancy include sterile sexual partner , hormonal contraceptive ( oral , injection , transdermal patch , implant ) , vaginal ring , intrauterine device ( IUD ) . 5 . Has general good health , confirm medical history physical examination . 6 . Had BCG vaccination , document medical history presence scar . 7 . Has share enclose live work space someone diagnose TB 3 month prior Study Day 0 . 8 . [ Cohorts 14 ] Does LTBI , determine negative QFT test screening . [ Cohorts 58 ] Has LTBI , determine positive QFT test screening . 1 . Acute illness Study Day 0 . 2 . Oral temperature &gt; 37.5 degree C Study Day 0 . 3 . Abnormal laboratory value recent blood collection prior Study Day 0 randomization equivalent Grade 2 toxicity , per protocol toxicity table , deem clinically significant . 4 . Severe anemia , define &lt; 10 g/dL hematocrit &lt; 30 % . 5 . Suspicion evidence ( include limit sputum Xpert MTB/RIF positive ) active TB disease site . An attempt must make obtain sputum participant ; person sputum unproductive assume Xpert MTB/RIF negative . 6 . History treatment TB disease . 7 . History autoimmune disease immunosuppression . 8 . Used immunosuppressive medication within 42 day Study Day 0 ( inhaled topical corticosteroid permit ) . 9 . Received immunoglobulin blood product within 42 day Study Day 0 . 10 . Received investigational drug investigational vaccine within 182 day Study Day 0 , plan participation investigational study study period . 11 . Received investigational Mtb vaccine time prior Study Day 0 . 12 . Planned administration/administration license vaccine period start 28 day end 28 day dose investigational product . 13 . History laboratory evidence past , present , future possible immunodeficiency state include limited laboratory indication HIV1 infection . 14 . History allergic disease reaction , include eczema , likely exacerbated component investigational product . 15 . Previous medical history may compromise safety participant study , include limited : impairment pulmonary function TB infection pulmonary disease ; chronic illness sign cardiac renal failure ; suspect progressive neurological disease ; uncontrolled epilepsy infantile spasm ; diabetes mellitus . 16 . History evidence physical examination systemic disease acute chronic illness , opinion investigator , may interfere evaluation safety immunogenicity vaccine , include axillary lymphadenopathy . 17 . Female participant : currently pregnant lactating/nursing ; positive urine pregnancy test screen prevaccination Study Day 0 . 18 . Any current medical , psychiatric , occupational , substance abuse problem , opinion investigator , could endanger participant make unlikely participant comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>